Evidence map›Paper›PMID 35684402›Full record

ArticleMolecules (Basel, Switzerland)2022

MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree.

Christine Bollwein, Juliana Pereira Lopes Gonҫalves, Kirsten Utpatel, Wilko Weichert, Kristina Schwamborn

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review
  6. Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Christine BollweinInstitute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.
Juliana Pereira Lopes GonҫalvesInstitute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.ORCID 0000-0002-6634-9876
Kirsten UtpatelInstitute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Wilko WeichertInstitute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.
Kristina SchwambornInstitute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.
Technical University of Munich · DEUniversity of Regensburg · DE

Funding

Deutsche Forschungsgemeinschaft 329628492
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma and cholangiocarcinoma constitute two aggressive tumor types that originate from the epithelial lining of the excretory ducts of the pancreatobiliary tract. Given their close histomorphological resemblance, a correct diagnosis can be challenging and almost impossible without clinical information. In this study, we investigated whether mass spectrometric peptide features could be employed to distinguish pancreatic ductal adenocarcinoma from cholangiocarcinoma. Three tissue microarrays of formalin-fixed and paraffin-embedded material (FFPE) comprising 41 cases of pancreatic ductal adenocarcinoma and 41 cases of cholangiocarcinoma were analyzed by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The derived peptide features and respective intensities were used to build different supervised classification algorithms: gradient boosting (GB), support vector machine (SVM), and k-nearest neighbors (KNN). On a pixel-by-pixel level, a classification accuracy of up to 95% could be achieved. The tentative identification of discriminative tryptic peptide signatures revealed proteins that are involved in the epigenetic regulation of the genome and tumor microenvironment. Despite their histomorphological similarities, mass spectrometry imaging represents an efficient and reliable approach for the distinction of PDAC from CC, offering a promising complementary or alternative approach to the existing tools used in diagnostics such as immunohistochemistry.

Indexed as

AdenocarcinomaBiliary TractCarcinoma, Pancreatic DuctalCholangiocarcinomaPancreatic NeoplasmsEpigenesis, GeneticHumansPancreasParaffin EmbeddingPeptidesSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationTumor MicroenvironmentPeptidescholangiocarcinomamachine learningMALDI-MSIpancreatic ductal adenocarcinomapeptidesproteomicssupervised classificationtandem mass spectrometry

Identifiers

PMID35684402
PMCPMC9182561
OpenAlexW4281658272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.